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PakistanIntroduction: Fluoroquinolones (FQ) are an essential component of current and new
regimens for the treatment of tuberculosis (TB). The 2014 Global TB report indicates a FQ
resistance rate of 17% amongst multidrug-resistant (MDR) strains of Mycobacterium
tuberculosis (MTB) tested in 2013. There is, however, a paucity of FQ-resistance data from
high burden countries. In this study the trend of FQ-resistance amongst MDR–MTB and
non-MDR–MTB is analyzed over a four-and-a-half-year period (January 2010–July 2014).
Methods: This study was conducted at the Aga Khan University laboratory, a technical part-
ner of the Pakistan National TB Program and part of the World Health Organization (WHO)
Supra-national Laboratory Network for TB. The laboratory receives specimens from across
the country through its peripheral collection units. MTB was isolated using standard
methods. Susceptibility testing was performed using the agar proportion method with drug
concentrations as recommended by Clinical Laboratory Institute Standards (CLSI). FQ sus-
ceptibilities were determined using ofloxacin (2 lg/ml). MTB H37Rv was used as a control
with each batch of susceptibility testing. MDR was defined as resistance to both isoniazid
(0.2 lg/ml) and rifampicin (1.0 lg/ml).
Results: During the study period 14,711 MTB strains were isolated. Of these, 6403 (43.5%)
were MDR and 8308 were non-MDR. FQ resistance in MDR strains ranged between 54%
and 58%.
Amongst non-MDR MTB strains, FQ resistance increased from 214/2059 (10.3%) in 2010 to
180/1049 (17.1%) in 2014. The proportion of FQ mono-resistant TB strains averaged at 10.5%
of the non-MDR isolates during this period.
Conclusions: FQ resistance in non-MDR–MTB strains with a considerable proportion of FQ
mono-resistant strains in Pakistan is alarming. These data highlight the limited potential
of empirical FQ usage for TB treatment in both MDR and non-MDR cases and the need to
implement regular surveillance for FQ-resistance in MTB in the country. High FQ resistance
amongst MTB isolates further emphasizes the importance of stewardship and the
responsible use of FQs in particular, and antimicrobials in general in the country.
 2015 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.
Table 1 – Fluoroquinolone resistance in MDR and non-MDR M.Tb isolates in Pakistan from 2010–2014.
2010 2011 2012 2013 2014
Jan–July
Total
Number of isolates per year (%)
MTB 3325 3129 3000 3390 1867 14711
MDR-TB 1266 1292 1347 1680 818 6403
FQ resistance in MDR-TB 691 (54.5) 742 (57.4) 779 (57.8) 914 (54.5) 441 (53.9) 3567 (55.7)
Non-MDR TB 2059 1837 1653 1710 1049 8308
FQ resistance in non MDR-TB 214 (10.3) 384 (20.9) 323 (19.5) 332 (19.4) 180 (17.1) 1433 (17.2)
FQ mono resistance 124 (6) 248 (13.5) 182 (11.1) 206 (12) 111 (10.5) 871 (10.5)
MTB: M.tuberculosis.
MDR-TB: Multi-drug resistant tuberculosis.
FQ: Fluoroquinolone.
48 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 4 ( 2 0 1 5 ) 4 7 –4 8
